Multidisciplinary

Top Medical News
Erenumab works well in chronic migraine patients across Asia
Jairia Dela Cruz, an hour ago
Erenumab proves to be effective at lowering the number of monthly migraine days in Asian patients with chronic migraine while having a favourable safety profile, according to the results of DRAGON study.
Laser superior to cryotherapy for hard-to-treat warts
2 hours ago
Use of long-pulsed neodymium-doped yttrium-aluminium-garnet (LP-Nd:YAG) laser provides similar overall therapeutic effects to those of cryotherapy, results of a recent study have shown. However, laser appears more effective against recalcitrant warts and results in shorter time to warts clearance.
Weekly somapacitan on par with daily growth hormone in children
Stephen Padilla, 3 hours ago
Weekly somapacitan is noninferior to daily growth hormone (GH) in terms of height velocity (HV), with comparable safety and mean insulin-like growth factor-1 standard deviation score (IGF-1 SDS) levels in treatment-naïve children with growth hormone deficiency (GHD), a study has shown.
Low choline intake ups risk of dementia, Alzheimer's disease
4 hours ago
Low intake of dietary choline may increase the risk of incident dementia and Alzheimer’s disease (AD), a recent study has found.
Healthy eating improves metabolic outcomes in obese kids
Tristan Manalac, 6 hours ago
In children and adolescents with obesity, keeping healthy diets and adhering to positive dietary behaviours appear to lead to better metabolic outcomes, according to a recent Singapore study.
Early menopause tied to increased dementia risk
7 hours ago
There appears to be no longitudinal association between hair cortisol and cortisone levels with dementia and various measures of cognitive function, a recent study has found.
Itraconazole effective for ringworm of the body but requires longer treatment
7 hours ago
Itraconazole appears to be effective in the treatment of patients with tinea corporis/cruris (TCC) or ringworm of the body, as shown in a study. However, the treatment duration needs to be longer and, even with successful treatment, many patients experience relapse.
Special Reports
A retrospective case series of ovarian stimulation
with follitropin delta in a mixed regimen with HP-hMG:
An interim analys
05 Dec 2022
Studies have shown that controlled ovarian stimulation (COS) supplementation with human chorionic gonadotropin (hCG)-driven luteinising hormone activity such as highly purified human menopausal gonadotropin (HP-hMG) (Menopur®) resulted in a significantly higher proportion of top-quality embryos and numbers of good-quality blastocysts compared with recombinant follicle-stimulating hormone (rFSH) alone. Regimens that combine FSH and hMG are often referred to as ‘mixed protocols’ and have been widely used for ovarian stimulation in the past decade. This single-centre, retrospective case series study aims to assess the efficacy of COS with follitropin delta in a mixed protocol regimen with HP-hMG in terms of the number of top-quality embryos and clinical pregnancy rate among Malaysian patients in a reproductive medicine clinic.
MANAGING INFECTIONS AMONG PATIENTS WITH MULTIPLE MYELOMA
05 Dec 2022
Managing infections in patients with multiple myeloma (MM)is important to improve their quality of life. Patients with MM are prone to infections due to the disease itself—the production of many malignant clonal plasma cells, which in turn, produce defective monoclonal antibodies.
Targeting the right patients in treatment of severe eosinophilic asthma and bringing balance to their lives.
05 Dec 2022
In conjunction with World Asthma Day and launch ofmepolizumab, GSK organised a webinar for healthcare professionals titled “The Right Patients at the Right Time: Elevating Care for SEA Patients with Biologics". Associate Professor Dr Mariko Koh Siyue, Senior Consultant in Respiratory and Critical Care Medicine, briefed the audience on severe eosinophilic asthma and discussed two case studies.
New Treatment Options for Multiple Myeloma Improves Patients’ Overall Survival, Quality of Life
05 Dec 2022
Multiple myeloma (MM) is a form of cancer where abnormal plasma cells, a type of white blood cell, accumulate in the bone marrow and replace the normal, healthy cells. While healthy plasma cells produce antibodies, cancerous plasma cells produce abnormal proteins, and the by-products of these proteins cause complications. New treatment options have transformed MM from an acute disease with a median survival of <6 months to a chronic condition where patients have better survival and quality of life (QOL).
ATTR-ACT LONG-TERM EXTENSION STUDY POINTS TO BETTER SURVIVAL OUTCOMES WITH TAFAMIDIS
01 Dec 2022
The recent ATTR-ACT long-term extension (LTE) study concluded that patients initially treated with tafamidis had significantly better survival than those initially treated with placebo, highlighting the significance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy (ATTR-CM).
Optimising Treatment in Myelofibrosis Lead to Greater Benefits
01 Dec 2022
At the recent 19th Malaysian Society of Haematology Scientific Meeting 2022, Professor Dr Martin Griesshammer presented an overview of the current paradigm surrounding myelofibrosis (MF) treatment and evidence that points to earlier initiation with JAK inhibition being beneficial for intermediate-1 patients.
Viatris: Braving the Future with a Solid Legacy
01 Dec 2022
While Viatris is a relatively new name among the pharmaceutical players, it is by no means a newcomer. The company is the result of the merger between Mylan and Upjohn, a legacy division of Pfizer. With the experience and brand legacy of two iconic powerhouses, Viatris is well-equipped to tackle the future. MIMS Doctor speaks to Jeff Bote, country manager of Viatris Malaysia, and learns a little about their direction and aspirations for the future.
Conference Reports
Midodrine a novel option for PICD prevention in ACLF
Elvira Manzano, 06 Dec 2022
Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.
Smoking cessation intervention during lung screening may encourage quitting
Roshini Claire Anthony, 05 Dec 2022

A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.

Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Roshini Claire Anthony, 04 Dec 2022

Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.

IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
Audrey Abella, 02 Dec 2022
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
Chinese herbal med cuts MACCE in STEMI, but questions remain
Elvira Manzano, 01 Dec 2022
Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.
Age, sex, syphilis risk factors for COVID-19 in PLHIV
Roshini Claire Anthony, 30 Nov 2022

Among people living with HIV (PLHIV), young women and patients with active syphilis appeared to be at an elevated risk of contracting COVID-19, according to a cross-sectional study presented at HIV Glasgow 2022.

FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 30 Nov 2022
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.